Vaccines to prevent neonatal GBS infection

Area of Science:

• Bacteriology
• Immunology
• Vaccinology

Background:

• Group B Streptococcus (GBS) is a primary cause of neonatal sepsis and meningitis in the US.
• Antibiotic prophylaxis reduces GBS infection rates but is not a long-term solution.
• Developing effective GBS vaccines is crucial for preventing neonatal disease.

Purpose of the Study:

• To develop and evaluate Group B Streptococcus (GBS) capsular polysaccharide (CPS)-protein conjugate vaccines.
• To assess the safety, immunogenicity, and efficacy of GBS conjugate vaccines in preclinical and clinical studies.

Main Methods:

• Production of GBS CPS-protein conjugate vaccines for all clinically significant serotypes.
• Immunization of animal models (mice and baboons) and human subjects in Phase 1 and 2 clinical trials.
• Evaluation of transplacental transfer of GBS-specific IgG antibodies and functional activity of elicited antibodies in vitro and in vivo.

Main Results:

• GBS CPS-protein conjugate vaccines were successfully produced for all serotypes.
• Transplacental transfer of functionally active GBS-specific IgG antibodies was observed in offspring of immunized animals.
• Phase 1 and 2 clinical trials demonstrated that GBS conjugate vaccines are safe, well-tolerated, and immunogenic in healthy adults.
• Antibodies elicited by the conjugate vaccines showed functional activity against invasive GBS disease in vitro and in animal models.

Conclusions:

• GBS CPS-protein conjugate vaccines represent a promising strategy for preventing neonatal GBS infections.
• The vaccines are safe and immunogenic in adults, with evidence of protective antibody transfer to offspring.
• Further development and implementation of these vaccines could significantly reduce the burden of GBS disease in newborns.